Combination of PAK1 inhibitors and CLK inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

The combination of PAK1 and CLK inhibitors addresses the challenge of chemotherapy resistance in AML by sensitizing chemoresistant cells to chemotherapy, thereby improving treatment outcomes for AML patients.

WO2025078334A1PCT designated stage expired Publication Date: 2025-04-17INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4
View PDF 18 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/078209
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-09
Filing Date
2024-10-08
Publication Date
2025-04-17

AI Technical Summary

Technical Problem

Chemotherapy resistance is a major therapeutic barrier in acute myeloid leukemia (AML), leading to poor prognosis and high relapse rates, with existing treatments failing to effectively eradicate chemoresistant leukemic clones.

Method used

The combination of PAK1 inhibitors and CLK inhibitors is administered to patients with chemoresistant AML to prevent resistance to chemotherapy and overcome relapses by targeting key regulators of splicing and cell survival pathways.

Benefits of technology

The combination of PAK1 and CLK inhibitors significantly enhances the sensitivity of chemoresistant AML cells to chemotherapy, reduces disease burden, and improves overall survival in preclinical models and refractory AML patient samples.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Chemotherapy resistance is the major therapeutic barrier in acute myeloid leukemia (AML). To address this issue, the inventors generated a syngeneic mouse model of AML, which we evolved to develop resistance to a front-line chemotherapy regimen. The inventors identified SRRM1 as a critical vulnerability of chemoresistant leukemic cells and identified that PAK1 and CLK kinases are regulators of SRRM1 in chemoresistant AML cells. Human and murine chemoresistant cells were found to be markedly more sensitive to inhibitors of PAKs (FRAX597) and CLKs (TG003 and ML 167) compared to their naive counterparts, an effect which was even further enhanced by treatment with cytarabine and daunorubicin. Simultaneous suppression of Clk1 and Pak1 or Clk-4 and Pak1 using validated shRNAs and combinations of FRAX597 and TG003, or FRAX597 and ML 167 synergized to reduce the growth and the colony-forming capacity of chemoresistant AML cells and sensitized them to chemotherapy. The combined treatment improved overall mouse survival and reduced disease burden in the chemoresistant AML mouse models. Moreover, AML patient cells that were primarily refractory or from a post chemotherapy relapse (n=21 ) exhibited a higher ex vivo sensitivity to the FRAX597 + TG003 combination in comparison with chemosensitive patients at diagnosis (n=28). Finally, combined PAK1 and CLK inhibition more effectively reduced disease progression in animals transplanted with the relapse sample than in those engrafted with the sample taken at diagnosis. Thus, the present invention relates to combination of PAK1 inhibitors and CLK inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] COMBINATION OF PAK1 INHIBITORS AND CLK INHIBITORS FOR PREVENTING RESISTANCE TO CHEMOTHERAPY IN PATIENTS SUFFERING FROM ACUTE MYELOID LEUKEMIA

[0002] FIELD OF THE INVENTION:

[0003] The present invention is in the field of medicine, in particular oncology.

[0004] BACKGROUND OF THE INVENTION:

[0005] Chemotherapy resistance is the major therapeutic barrier in acute myeloid leukemia (AML). AML is the most common adult leukemia. It is characterized by clonal expansion of immature myeloblasts and initiates from rare leukemic stem cells (LSCs). Despite a high rate of complete remission after conventional front-line induction chemotherapy (e.g. daunorubicin, DNR, or idarubicin, IDA plus cytarabine, AraC), the prognosis is very poor in AML. To date, 5- year overall survival is still about 30 to 40% in patients younger than 60 years old and less than 20% in patients over 60 years. This results from the high frequency of distant relapses (50 and 85% before and after the age of 60, respectively) caused by tumor regrowth initiated by chemoresistant leukemic clones (RLCs) and characterized by a refractory phase during which no other treatment has shown any efficacy thus far. AML is one of the rare hematological malignancies, for which therapy has not significantly improved during the past 30 years despite intense research efforts. Therefore, understanding the causes of chemoresistance is crucial for the development of new treatments eradicating RLCs to overcome AML patient relapses.

[0006] SUMMARY OF THE INVENTION:

[0007] The present invention is defined by the claims. In particular, the present invention relates to combination of PAK1 inhibitors and CLK inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia.

[0008] DETAILED DESCRIPTION OF THE INVENTION:

[0009] The first object of the present invention relates to a method of treating chemoresistant acute myeloid leukemia (AML) in a patient in need thereof comprising administering to the patient a therapeutically effective combination comprising a PAK1 inhibitor and a CLK inhibitor. As used herein, the term “patient” is interchangeable with the term “individual” or “subject”, and may refer to a patient to be treated by the methods disclosed herein. In particular, the patient suffers from an AML. In some embodiments, the patient is a human infant. In some embodiments, the patient is a human child. In some embodiments, the patient is a human adult. In some embodiments, the patient is an elderly.

[0010] As used herein, the term "acute myeloid leukemia" or "acute myelogenous leukemia" or "AML" has its general meaning in the art and refers to a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

[0011] As used herein; the term "chemoresistant acute myeloid leukemia" or “chemoresistant AML” refers to the clinical situation in a patient suffering from an AML when the proliferation of leukemic cells cannot be prevented or inhibited by means of a chemotherapeutic agent or a combination of chemotherapeutic agents usually used to treat AML, at an acceptable dose to the patient. Thus, the expression "resistance to chemotherapy" is used in its broadest context to refer to the reduced effectiveness of chemotherapy to inhibit the growth of a leukemic cell, kill a leukemic cell or inhibit one or more cellular functions, and to the ability of a cell to survive exposure to an agent designed to inhibit the growth of the leukemic cell, kill the leukemic cell or inhibit one or more cellular functions. The leukemia can be intrinsically resistant prior to chemotherapy, or resistance may be acquired during treatment of leukemia that is initially sensitive to chemotherapy. The resistance displayed by a leukemic cell may be complete in that the chemotherapy is rendered completely ineffective against the leukemic cell, or may be partial in that the effectiveness of the chemotherapy is reduced. The phrase “preventing resistance to chemotherapy” or “overcoming resistance to chemotherapy” in context of the invention shall be effective if compared to a non-treated control, the leukemic cells become more sensitive to chemotherapy. In particular, the patient become a responder. As used herein the term “responder” in the context of the present disclosure refers to a patient that will achieve a response, i.e. a patient where the leukemia is eradicated, reduced or improved after immunotherapy. According to the invention, the responders have an objective response and therefore the term does not encompass patients having a stabilized cancer such that the disease is not progressing after immunotherapy. A “non-responder” or “refractory patient” includes patients for whom the leukemia does not show reduction or improvement after chemotherapy. The term “non responder” also includes patients having a stabilized leukemia. Typically, the characterization of the patient as a responder or non-responder can be performed by reference to a standard or a training set. The standard may be the profile of a patient who is known to be a responder or non-responder or alternatively may be a numerical value. Such predetermined standards may be provided in any suitable form, such as a printed list or diagram, computer software program, or other media. When it is concluded that the patient is a non-responder, the physician could take the decision to administer the patient with a therapeutically effective combination comprising a PAK1 inhibitor and a CLK inhibitor.

[0012] As used herein, the term “chemotherapy” has its general meaning in the art and refers to the treatment that consists in administering to the patient a chemotherapeutic agent. As used herein, the term "chemotherapeutic agent" refers to any chemical agent with therapeutic usefulness in the treatment of cancer. Chemotherapeutic agents as used herein encompass both chemical and biological agents. These agents function to inhibit a cellular activity upon which the leukemic cell depends for continued survival. Categories of chemotherapeutic agents include alkylating / alkaloid agents, antimetabolites, hormones or hormone analogs, and miscellaneous antineoplastic drugs. Most if not all of these drugs are directly toxic to leukemic cells and do not require immune stimulation. Suitable chemotherapeutic agents are described, for example, in Slapak and Kufe, Principles of Cancer Therapy, Chapter 86 in Harrison's Principles of Internal medicine, 14th edition; Perry et at , Chemotherapeutic, Ch 17 in Abel off, Clinical Oncology 2nd ed., 2000 ChrchillLivingstone, Inc.; Baltzer L. and Berkery R. (eds): Oncology Pocket Guide to Chemotherapeutic, 2nd ed. St. Louis, mosby- Year Book, 1995; Fischer D. S., Knobf M. F., Durivage HJ. (eds): The Cancer Chemotherapeutic Handbook, 4th ed. St. Louis, Mosby-Year Handbook.

[0013] In some embodiments the chemotherapeutic agent is cytarabine (cytosine arabinoside, Ara-C, Cytosar-U), quizartinib (AC220), sorafenib (BAY 43-9006), lestaurtinib (CEP-701), midostaurin (PKC412), carboplatin, carmustine, chlorambucil, dacarbazine, ifosfamide, lomustine, mechlorethamine, procarbazine, pentostatin, (2'deoxycoformycin), etoposide, teniposide, topotecan, vinblastine, vincristine, paclitaxel, dexamethasone, methylprednisolone, prednisone, all- trans retinoic acid, arsenic trioxide, interferon-alpha, rituximab (Rituxan®), gemtuzumab ozogamicin, imatinib mesylate, Cytosar-U), melphalan, busulfan (Myleran®), thiotepa, bleomycin, platinum (cisplatin), cyclophosphamide, Cytoxan®)., daunorubicin, doxorubicin, idarubicin, mitoxantrone, 5-azacytidine, cladribine, fludarabine, hydroxyurea, 6- mercaptopurine, methotrexate, 6-thioguanine, or any combination thereof. In some embodiments, the chemotherapy consists in a combination of cytarabine and an anthracycline such as daunorubicin or idarubicin.

[0014] As used herein, the term "treatment" or "treat" refer to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of patient at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse. The treatment may be administered to a patient having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a patient beyond that expected in the absence of such treatment. By "therapeutic regimen" is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy. A therapeutic regimen may include an induction regimen and a maintenance regimen. The phrase "induction regimen" or "induction period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease. The general goal of an induction regimen is to provide a high level of drug to a patient during the initial period of a treatment regimen. An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both. The phrase "maintenance regimen" or "maintenance period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a patient during treatment of an illness, e.g., to keep the patient in remission for long periods of time (months or years). A maintenance regimen may employ continuous therapy (e.g., administering a drug at regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).

[0015] A further object of the present invention relates to a method of preventing resistance to chemotherapy in a patient suffering from an acute myeloid leukemia (AML) comprising administering to the patient a therapeutically effective combination comprising a PAK1 inhibitor and a CLK inhibitor. A further object of the present invention relates to a method of preventing relapse in a patient suffering from an AML and who was treated by chemotherapy comprising administering to the patient a therapeutically effective combination comprising a PAK1 inhibitor and a CLK inhibitor.

[0016] As used herein, the term “relapse” refers to reappearance of the leukemia after an initial period of responsiveness (e.g., complete response or partial response). The initial period of responsiveness may involve the level of leukemic cells falling below a certain threshold, e.g., below 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1%. The reappearance may involve the level of leukemic cells rising above a certain threshold, e.g., above 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1%. More generally, a response (e.g., complete response or partial response) can involve the absence of detectable MRD (minimal residual disease).

[0017] As used herein the term “PAK1” has its general meaning in the art and refers to the p21- activated kinase 1. PAK1 is a protein kinase that plays a crucial role in various cellular processes, including cell growth, cell motility, cell division, and cytoskeletal reorganization. It is part of a family of serine / threonine kinases known as p21 -activated kinases (PAKs) that are involved in intracellular signaling pathways.

[0018] As used herein, the term "PAK1 inhibitor" refers to any compound that (i) directly interact with PAK1, e.g., by binding to PAK1 and (ii) decrease the expression or the activity of PAK1. A PAK1 inhibitor may be any type of molecule, including, but not limited to, small molecules, antibodies and expression modulators (such as antisense molecules, microRNAs, siRNAs, aptamers, etc.), and may act directly on the PAK1 protein, may interfere with expression of the PAK1 protein (e.g., transcription, splicing, translation, and / or post-translational processing), and / or may prevent improper intracellular localization and / or membrane translocation, and / or phosphorylation and / or activation of the PAK1 protein. PAK1 inhibitors are well known in the art (see e.g. Semenova G, Chernoff J. Targeting PAK1. Biochem Soc Trans. 2017 Feb 8;45(l):79-88. doi: 10.1042 / BST20160134. PMID: 28202661; PMCID: PMC5973817 or Senapedis ffl, Crochiere M, BalogluE, Lande sman Y. Therapeutic Potential of Targeting PAK Signaling. Anticancer Agents Med Chem. 2016; 16(l):75-88. doi: 10.2174 / 1871520615666150617111414. PMID: 26081410). Example of PAK1 inhibitors include the compounds described in W02004007504, W02006072831, W02007023382, W02007072153, W02009086204, W02010071846, WO20 11044264, WO2011044535, WO2011156640, WO2011156646, WO2011156775, WO201 1156780, WO2011156786, and WO 2013026914. More particularly, examples of PAK1 inhibitors include but are not limited to IP A3 (1,1’ -Dithiodi -2 -naphthtol), AG-1478 (N- (3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinanine), FRAX597 (6-[2-chloro-4-(l,3-thiazol-5- yl)phenyl]-8-ethyl-2-[4-(4-methylpiperazin-l-yl)anilino]pyrido[2,3-d]pyrimidin-7-one), FRAX486 (6-(2,4-Dichlorophenyl)-8-ethyl-2-[[3-fluoro-4-(l- piperazinyl)phenyl]amino]pyrido[2,3 -d]pyrimidin-7(8H)-one), PF-3758309 ((S) — N-(2-

[0019] (dimethylamino)-l-phenylethyl)-6,6-dimethyl-3-((2-methylthieno[3,2-d]pyrimidin-4- yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(lH)-carboxamide), and 8-[(trans-5-Amino- l,3-dioxan-2-yl)methyl]-6-[2-chloro-4-(6-methyl-2-pyridinyl)phenyl]-2-(methylamino)- pyrido[2,3 -d]pyrimidin-7(8H)-one (G-5555).

[0020] As used herein, the term “CLK” refers to the family of cdc2-like kinases (CLKs). The CLKs are dual-specificity kinases (tyrosine and serine / threonine kinases) of the CMGC family (cyclin-dependent kinases, mitogen-activated kinases, glycogen synthase kinases, and CDK- like kinases). There are four mammalian isoforms, CLK1-4, with different substrate targets.

[0021] As used herein, the term "CLK inhibitor" refers to any compound that (i) directly interact with cdc2-like kinase, e.g., by binding to the CLK and (ii) decrease the expression or the activity of the CLK. A CLK inhibitor may be any type of molecule, including, but not limited to, small molecules, antibodies and expression modulators (such as antisense molecules, microRNAs, siRNAs, aptamers, etc.), and may act directly on the CLK protein, may interfere with expression of the CLK protein (e.g., transcription, splicing, translation, and / or post-translational processing), and / or may prevent improper intracellular localization and / or membrane translocation, and / or phosphorylation and / or activation of the CLK protein. CLK inhibitor are well known (see e.g. PrakK, Kriston-Vizi J, Chan AW, Luft C, Costa JR, Pengo N, Ketteler R. Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members. Biochemistry. 2016 Jan 26;55(3):608-17. doi: 10.1021 / acs.biochem.5b01128. Epub 2016 Jan 5. PMID: 26701387; PMCID: PMC4730229, Mucka P, Lindemann P, Bosco B, Willenbrock M, Radetzki S, Neuenschwander M, Brischetto C, Peter von Kries J, Nazare M, Scheidereit C. CLK2 and CLK4 are regulators of DNA damage-induced NF-KB targeted by novel small molecule inhibitors. Cell Chem Biol. 2023 Jul 15:52451-9456(23)00205-2. doi: 10.1016 / j.chembioL2023.06.027. Epub ahead of print. PMID: 375067 1. and ElHady AK, El- Gamil DS, Abadi AH, Abdel-Halim M, Engel M. An overview of cdc2-like kinase 1 (Clkl) inhibitors and their therapeutic indications. Med Res Rev. 2023 Mar;43(2):343-398. doi: 10.1002 / med.21928. Epub 2022 Oct 19. PMID: 36262046.

[0022] Example of CLK inhibitors include the compounds described in WO2017188374 and W02020006115. More particularly, examples of CLK inhibitors include but are not limited to (lZ)-l-(3-Ethyl-5-methoxy-2(3H)-benzothiazolylidene)-2 -propanone (TG003), 3-(3-

[0023] Chlorophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(lH)-one (KuWall51), ethyl 3-(2-Amino-l- cyanoethenyl)-6,7-dichloro-l-methylindole-2-carboxylate (KH CB19) and 5-[4-[[(5-Methyl-2- furanyl)methyl]amino]-6-quinazolinyl]-2 -furanmethanol (ML 167).

[0024] As used herein, the term “combination” is intended to refer to all forms of administration that provide a first drug together with a further (second, third...) drug. The drugs may be administered simultaneous, separate or sequential and in any order. Drugs administered in combination have biological activity in the subject to which the drugs are delivered. Within the context of the invention, a combination thus comprises at least two different drugs, and wherein one drug is at least a PAK1 inhibitor and wherein the other drug is a CLK inhibitor. In some instance, the combination of the present invention results in the synthetic lethality of the leukemic cells, in particular DTC.

[0025] As used herein, the expression "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. A therapeutically effective amount of drug may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of drug to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects. The efficient dosages and dosage regimens for drug depend on the disease or condition to be treated and may be determined by the persons skilled in the art. A physician having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician could start doses of drug employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In general, a suitable dose of a composition of the present invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect according to a particular dosage regimen. Such an effective dose will generally depend upon the factors described above. For example, a therapeutically effective amount for therapeutic use may be measured by its ability to stabilize the progression of disease. A therapeutically effective amount of a therapeutic compound may decrease tumor size, or otherwise ameliorate symptoms in a subject. One of ordinary skill in the art would be able to determine such amounts based on such factors as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected. An exemplary, non-limiting range for a therapeutically effective amount of drug is about 0.1-100 mg / kg, such as about 0.1-50 mg / kg, for example about 0.1-20 mg / kg, such as about 0.1-10 mg / kg, for instance about 0.5, about such as 0.3, about 1, about 3 mg / kg, about 5 mg / kg or about 8 mg / kg. An exemplary, non-limiting range for a therapeutically effective amount of an antibody of the present invention is 0.02-100 mg / kg, such as about 0.02-30 mg / kg, such as about 0.05-10 mg / kg or 0.1-3 mg / kg, for example about 0.5-2 mg / kg. Administration may e.g. be intravenous, intramuscular, intraperitoneal, or subcutaneous, and for instance administered proximal to the site of the target. Dosage regimens in the above methods of treatment and uses are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. In some embodiments, the efficacy of the treatment is monitored during the therapy, e.g. at predefined points in time. As non-limiting examples, treatment according to the present invention may be provided as a daily dosage of the agent of the present invention in an amount of about 0.1-100 mg / kg, such as 0.2, 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90 or 100 mg / kg, per day, on at least one of days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, or alternatively, at least one of weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 after initiation of treatment, or any combination thereof, using single or divided doses every 24, 12, 8, 6, 4, or 2 hours, or any combination thereof.

[0026] Typically, the drug of the present invention is administered to the subject in the form of a pharmaceutical composition which comprises a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers that may be used in these compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene- block polymers, polyethylene glycol and wool fat. For use in administration to a subject, the composition will be formulated for administration to the subject. The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Sterile injectable forms of the compositions of this invention may be aqueous or an oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation. The compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include, e.g., lactose. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added. Alternatively, the compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols. The compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs. For topical applications, the compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyl dodecanol, benzyl alcohol and water. Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Patches may also be used. The compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well- known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents. For example, an antibody present in a pharmaceutical composition of this invention can be supplied at a concentration of 10 mg / mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. The product is formulated for IV administration in 9.0 mg / mL sodium chloride, 7.35 mg / mL sodium citrate dihydrate, 0.7 mg / mL polysorbate 80, and Sterile Water for Injection. The pH is adjusted to 6.5. An exemplary suitable dosage range for an antibody in a pharmaceutical composition of this invention may between about 1 mg / m2and 500 mg / m2. However, it will be appreciated that these schedules are exemplary and that an optimal schedule and regimen can be adapted taking into account the affinity and tolerability of the particular antibody in the pharmaceutical composition that must be determined in clinical trials. A pharmaceutical composition of the invention for injection (e.g., intramuscular, i.v.) could be prepared to contain sterile buffered water (e.g. 1 ml for intramuscular), and between about 1 ng to about 100 mg, e.g. about 50 ng to about 30 mg or more preferably, about 5 mg to about 25 mg, of the inhibitor of the invention.

[0027] A further object of the present invention relates to a pharmaceutical composition or a kit (kit- of-parts) comprising a CLK inhibitor and a PAK1 inhibitor, in particular for use for AML.

[0028] The terms “kit” or "combined preparation", as used herein, defines especially a "kit-of-parts" in the sense that the combination partners as defined above can be dosed independently or by use of different fixed combinations with distinguished amounts of the combination partners, i.e. simultaneously or at different time points. The parts of the kit-of-parts can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts. The ratio of the total amounts of the combination partners to be administered in the combined preparation can be varied. The combination partners can be administered by the same route or by different routes.

[0029] The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.

[0030] EXAMPLE:

[0031] In Acute Myeloid Leukemia (AML), distinguishing between chemoresistance driver mechanisms and cell plasticity in response to chemotherapy is challenging due to their interconnectedness. To address this issue, we generated an LZ-AFP-driven syngeneic mouse model of AML, which we evolved to develop resistance to a front-line chemotherapy regimen by repetitive exposure to a maximally -tolerated combination of cytarabine and doxorubicin. An RNA sequencing (RNAseq)-based profiling of the chemoresistant (ChemoR) AML subpopulation and its naive (ChemoN) counterpart revealed a significant upregulation in the expression of 559 genes in ChemoRcells which were markedly enriched in gene sets related to splicing / mRNA processing. Notably, single-sample GSEA analysis of relapsed AML samples from the BEAT -AML cohort supported these findings, as they were enriched for the upregulation of genes in our chemoresistance gene signature. A combined in vivo functional screening endeavor using a pool of 2098 shRNAs targeting these upregulated genes and a motif discovery analysis performed on the set of dysregulated transcripts in ChemoRcells identified three candidate hits, Srrm Sf3b3, and Prpf8, which scored as chemotherapy-specific dependencies and were found to interact with central regulators of alternative splicing. Silencing these three candidate genes in our chemoresistant mouse model and the human AML cell lines, MOLM-14, MV4-11, and U937, evolved to become resistant to the combination of cytarabine and daunorubicin, revealed that the splicing regulator, SRRM1, is a critical vulnerability of chemoresistant leukemic cells.

[0032] An orthogonal phospho-proteomic approach identified that PAK1 and CLK kinases are regulators of SRRM1 in chemoresistant AML cells, through the phosphorylation of multiple serine and threonine phosphosites in its arginine-rich domain. Human and murine chemoresistant cells were found to be markedly more sensitive to inhibitors of PAKs (FRAX597) and CLKs (TG003 and ML 167) compared to their naive counterparts, an effect which was even further enhanced by treatment with cytarabine and daunorubicin. Notably, a whole-exome sequencing pipeline at our institution revealed a clonal variant of uncertain significance (c.1429G>T p.(Ala477Ser)) in PAK1 in an AML patient at relapse. Absence of this variant at diagnosis suggested its association with chemotherapy resistance. Biochemical and cellular assays confirmed that the A477S variant increased PAK1 activation as well as chemotherapy resistance in AML cell lines. This effect could be counteracted by suppressing SRRM1, indicating that PAK1 activation in relapsed AML confers increased vulnerability to SRRM1 suppression.

[0033] Simultaneous suppression of Clkl and Pakl or Clk4 and Pakl using validated shRNAs and combinations of FRAX597 and TG003, or FRAX597 and ML167 synergized to reduce the growth and the colony-forming capacity of chemoresistant AML cells and sensitized them to chemotherapy. These observations were supported by the RNAseq-based estimate of the inclusion ratios of alternative exons and introns which showed that the combination of PAK and CLK inhibitors phenocopied partially the effects of SRRM1 silencing on splicing perturbations. In preclinical studies, the combined treatment improved overall mouse survival and reduced disease burden in our chemoresistant AML mouse models compared to single-drug treatments. Moreover, AML patient cells that were primarily refractory or from a post chemotherapy relapse (n=21) exhibited a higher ex vivo sensitivity to the FRAX597 + TG003 combination in comparison with chemosensitive patients at diagnosis (n=28). Moreover, in NSG-S mice transplanted with matched samples from the same AML patient at diagnosis and relapse post-chemotherapy, combined PAK1 and CLK inhibition more effectively reduced disease progression in animals transplanted with the relapse sample than in those engrafted with the sample taken at diagnosis. In conclusion, our study advances the rationale that combined inhibition of PAK1 and CLK kinases effectively curtails malignant cell splicing adaptation to chemotherapy by affecting SRRM1 function. Combined PAK1 and CLK inhibitors either concomitant with or sequential to chemotherapy may offer greater clinical benefit and significantly improve AML patients’ long-term outcomes.

[0034] REFERENCES:

[0035] Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.

Claims

CLAIMS:

1. A method of treating chemoresistant acute myeloid leukemia (AML) in a patient in need thereof comprising administering to the patient a therapeutically effective combination comprising a PAK1 inhibitor and a CLK inhibitor.

2. A method of preventing resistance to chemotherapy in a patient suffering from an acute myeloid leukemia (AML) comprising administering to the patient a therapeutically effective combination comprising a PAK1 inhibitor and a CLK inhibitor.

3. A method of preventing relapse in a patient suffering from an AML and who was treated by chemotherapy comprising administering to the patient a therapeutically effective combination comprising a PAK1 inhibitor and a CLK inhibitor.

4. The method according to any one of claims 1 to 3 wherein the chemotherapy consists in a combination of cytarabine and an anthracycline such as daunorubicin or idarubicin.

Citation Information

Patent Citations

  • Heterobicyclic pyrazole derivatives as kinase inhibitors

    WO2004007504A1

  • Pyrrolopyrazoles, potent kinase inhibitors

    WO2006072831A1

  • Pyrimidine amino pyrazole compounds, potent kinase inhibitors

    WO2007023382A2

  • Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

    WO2007072153A2

  • Methods for treating neuropsychiatric conditions

    WO2009086204A2